Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 969 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Group Regimen Clear all
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

NCT02543268
View directory record Official record
Conditions
Healthy
Interventions
Ad26.ZEBOV-Batch #1, Ad26.ZEBOV-Batch #2, Ad26.ZEBOV-Batch #3, MVA-BN-Filo, Placebo
Biological
Lead sponsor
Crucell Holland BV
Industry
Eligibility
18 Years to 50 Years
Enrollment
329 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
6
States / cities
Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2025 · Synced Oct 22, 2026, 4:32 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Different Combinations of Zonisamide-CR Plus Bupropion-SR to Treat Uncomplicated Obesity

NCT00339014
View directory record Official record
Conditions
Obesity
Interventions
Zonisamide CR and Bupropion SR, Placebo
Drug · Other
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
15
States / cities
Fairhope, Alabama • Los Angeles, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2008 · Synced Oct 22, 2026, 4:32 AM EDT
Completed Phase 4 Interventional Results available

Minimal Opioid Use After Total Hip Replacement (THR)

NCT03090152
View directory record Official record
Conditions
Osteoarthritis, Hip
Interventions
Periarticular injection (Deep injection), Periarticular injection (Superficial injection), Bupivacaine, Placebo
Procedure · Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
50 Years to 75 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 22, 2026, 4:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Pharmacokinetics, Safety, and Tolerability of Intravenous ETX2514 and Sulbactam Administered Concurrently to Subjects With Various Degrees of Renal Impairment and Healthy Matched Control Subjects

NCT03310463
View directory record Official record
Conditions
Acinetobacter Baumannii Infection
Interventions
ETX2514SUL
Drug
Lead sponsor
Entasis Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
3
States / cities
Lakewood, Colorado • Miami, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 22, 2026, 4:32 AM EDT
Completed Phase 3 Interventional Results available

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea

NCT00713830
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Lixisenatide (AVE0010), Placebo, Pen auto-injector, Sulfonylurea, Metformin
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
859 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Oct 22, 2026, 4:32 AM EDT
Completed Phase 2 Interventional Results available

Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact Dermatitis

NCT00928447
View directory record Official record
Conditions
Dermatitis, Allergic Contact
Interventions
rHuPH20, Placebo
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Michigan City, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Oct 22, 2026, 4:32 AM EDT
Active, not recruiting No phase listed Observational

MEtabolic and Renal Effects of AutoMAted Insulin Delivery Systems in Youth With Type 1 Diabetes Mellitus

NCT03945747
View directory record Official record
Conditions
Type1 Diabetes Mellitus, Diabetes Mellitus, Type 1, Autoimmune Diabetes, Juvenile Diabetes, Diabetes Mellitus Complication, Diabetic Nephropathies, Metabolic Disease, Diabetic Kidney Disease
Interventions
Blood draw, Urine sample collection, DXA scan
Diagnostic Test
Lead sponsor
University of Colorado, Denver
Other
Eligibility
7 Years to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 22, 2026, 4:32 AM EDT
Recruiting Not applicable Interventional

IMST for Dementia Risk Reduction

NCT07349706
View directory record Official record
Conditions
Systolic Blood Pressure, Blood Pressure, Depression - Major Depressive Disorder, Anxiety, Sleep Quality, Physical Function, Cognitive Function
Interventions
Inspiratory Muscle Strength Training High-Resistance, Inspiratory Muscle Strength Training Low-Resistance
Device
Lead sponsor
Florida State University
Other
Eligibility
60 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 22, 2026, 4:32 AM EDT
Terminated Not applicable Interventional

Study to Intervene With Nutrition for Gastroparesis

NCT03987672
View directory record Official record
Conditions
Gastroparesis
Interventions
Assess the nutritional effects of the Kate Farm Peptide 1.5 nutritional Formula
Dietary Supplement
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Oct 22, 2026, 4:32 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)

NCT01597245
View directory record Official record
Conditions
Psoriasis
Interventions
80 mg ixekizumab Dosing Regimen, 50 mg etanercept, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
41
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2020 · Synced Oct 22, 2026, 4:32 AM EDT
Completed Not applicable Interventional Results available

Early Cognitive Intervention in Delirium

NCT04740567
View directory record Official record
Conditions
Delirium, Cognitive Decline, Dementia
Interventions
Cognitive Training, Goal Management Training
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
65 Years and older
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 22, 2026, 4:32 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia

NCT00463385
View directory record Official record
Conditions
Myelofibrosis With Myeloid Metaplasia, Myeloid Metaplasia, Myelofibrosis
Interventions
Pomalidomide, Prednisone, Placebo to pomalidomide, Placebo to prednisone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
6
States / cities
Los Angeles, California • Rochester, Minnesota • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Oct 22, 2026, 4:32 AM EDT
Terminated Phase 1 Interventional

Dopamine D2/D3 Receptor Upregulation by Varenicline in Methamphetamine Users

NCT03059563
View directory record Official record
Conditions
Dopamine D2/3 Receptor Availability, Cognitive Function, Methamphetamine Abuse
Interventions
Varenicline, Placebo
Drug · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 60 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 22, 2026, 4:32 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Exendin 9-39 in Patients With Postbariatric Hypoglycemia

NCT03373435
View directory record Official record
Conditions
Postbariatric Hypoglycemia
Interventions
exendin 9-39, Placebo
Drug · Other
Lead sponsor
Eiger BioPharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Palo Alto, California • Aurora, Colorado • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Oct 22, 2026, 4:32 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans

NCT04313634
View directory record Official record
Conditions
Healthy
Interventions
Dasatinib, Quercetin, Fisetin
Drug
Lead sponsor
Sundeep Khosla, M.D.
Other
Eligibility
60 Years and older · Female only
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Oct 22, 2026, 4:32 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.

NCT05158387
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Tozorakimab, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
1,172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
34
States / cities
Sheffield, Alabama • Lincoln, California • Newport Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 22, 2026, 4:32 AM EDT
Completed Not applicable Interventional

Increasing HCV Linkage to Care Among People Who Inject Drugs

NCT04741750
View directory record Official record
Conditions
Hepatitis C
Interventions
Simplified HCV care within a mobile medical unit
Other
Lead sponsor
Family Health Centers of San Diego
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2024 · Synced Oct 22, 2026, 4:32 AM EDT
Completed Phase 2 Interventional Results available

ALS Reversals - Lunasin Regimen

NCT02709330
View directory record Official record
Conditions
ALS (Amyotrophic Lateral Sclerosis)
Interventions
Lunasin Regimen, Historical control
Drug · Other
Lead sponsor
Richard Bedlack, M.D., Ph.D.
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Oct 22, 2026, 4:32 AM EDT
Completed Phase 4 Interventional Results available

Vitamin D Repletion in Primary Hyperparathyroidism

NCT01306656
View directory record Official record
Conditions
Primary Hyperparathyroidism, Vitamin D Deficiency
Interventions
10,000 IU Vitamin D3, Placebo, Vitamin D
Drug · Other · Dietary Supplement
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 22, 2026, 4:32 AM EDT
Withdrawn Phase 1 Interventional

Examination of Whether Host Preconditioning Modifies Short-term Transplant Survival

NCT01960764
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Pre-Treatment with Dial liquid antibacterial soap, Control
Drug · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Oct 22, 2026, 4:32 AM EDT
Completed Phase 2 Interventional Results available

Safety, Efficacy and Treatment Regimen Study of ST266 in Subjects With Moderate to Severe Periodontitis

NCT02761993
View directory record Official record
Conditions
Periodontal Disease
Interventions
ST266, Saline (0.9% NaCl)
Biological · Drug
Lead sponsor
Noveome Biotherapeutics, formerly Stemnion
Industry
Eligibility
18 Years to 85 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
6
States / cities
Birmingham, Alabama • Indianapolis, Indiana • Cambridge, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Oct 22, 2026, 4:32 AM EDT
Active, not recruiting Phase 3 Interventional

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response

NCT06641089
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Sonelokimab, Placebo, Risankizumab
Drug
Lead sponsor
MoonLake Immunotherapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
44
States / cities
Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 22, 2026, 4:32 AM EDT
Completed Phase 3 Interventional Results available

Exubera vs Lispro in a Lantus-based Regimen for Improved Glycemic Control in Type 2 Diabetes

NCT00348374
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Insulin Lispro, Exubera
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
62
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2010 · Synced Oct 22, 2026, 4:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Optimization of the Bowel Preparation Regimen for the PillCam® COLON 2 Capsule Endoscopy Procedure

NCT02481219
View directory record Official record
Conditions
Colorectal Cancer Screening
Interventions
PillCam® COLON 2 procedure-CONTROL, Senna tablets, PEG, Metoclopramide, Erythromycin, SUPREP oral sulfate solution, Bisacodyl, SUPREP oral sulfate solution with Gastrografin
Device · Drug
Lead sponsor
Medtronic - MITG
Industry
Eligibility
50 Years to 75 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
6
States / cities
Anniston, Alabama • Indianapolis, Indiana • Dayton, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Oct 22, 2026, 4:32 AM EDT